Access cutting-edge macular degeneration treatment through this clinical trial at a research site in Cincinnati. Study-provided care at no cost to qualified participants.
Access macular degeneration specialists in Cincinnati at no cost
This study follows strict safety protocols and ethical guidelines
All study-related macular degeneration treatment provided free
This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD).
Sponsor: Neuracle Genetics, Inc
Check if you qualify for this macular degeneration clinical trial in Cincinnati, OH
If you're searching for macular degeneration treatment options in Cincinnati, OH, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Cincinnati research site is actively enrolling participants for this clinical trial. You'll receive care from experienced macular degeneration specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.